Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Rito Bergemann

A Phase 3 Clinical Trial With ISIS-TTRRx, a 2nd-Generation Antisense Oligonucleotide Targeting Transthyretin (TTR), for the Treatment of TTR Amyloid Cardiomyopathy

Orphanet Journal of Rare Diseases

English

Related publications

Treatment of Transthyretin (TTR) Amyloid Cardiomyopathy With an Antisense Oligonucleotide Inhibitor of TTR Synthesis

Orphanet Journal of Rare Diseases

English

Accelerated a Deposition in APPswe/PS1 E9 Mice With Hemizygous Deletions of TTR (Transthyretin)

Journal of Neuroscience

Neuroscience

2007

English

Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area

Journal of Neuromuscular Diseases

Neurology

2015

English

Late-Onset Transthyretin (TTR)-familial Amyloid Polyneuropathy (FAP) With a Long Disease Duration From Non-Endemic Areas in Japan

Internal Medicine

Medicine

2019

English

The Prevalence and Distribution of the Amyloidogenic Transthyretin (TTR) V122I Allele in Africa

Molecular genetics & genomic medicine

Genetics

Molecular Biology

2016

English

Autosomal-Dominant Transthyretin (TTR)-related Amyloidosis Is Not a Frequent CMT2 Neuropathy “In Disguise”

Orphanet Journal of Rare Diseases

English

Extrapolation of Data From the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) Further Highlights the Survival Benefit of Tafamidis in Transthyretin Amyloid Cardiomyopathy

Journal of Cardiac Failure

Cardiovascular Medicine

Cardiology

2019

English

Refine Penetrance Estimates in the Main Pathogenic Variants of Transthyretin Hereditary (Familial) Amyloid Polyneuropathy (TTR-FAP) Using a New Non-Parametric Approach (NPSE)

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Internal Medicine

Medicine

2017

English

A Case of Familial Amyloid Polyneuropathy Due to Phe33Val TTR With Vitreous Involvement as the Initial Manifestation

Internal Medicine

Medicine

2010

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Rito Bergemann

A Phase 3 Clinical Trial With ISIS-TTRRx, a 2nd-Generation Antisense Oligonucleotide Targeting Transthyretin (TTR), for the Treatment of TTR Amyloid Cardiomyopathy

Related publications

Treatment of Transthyretin (TTR) Amyloid Cardiomyopathy With an Antisense Oligonucleotide Inhibitor of TTR Synthesis

Accelerated a Deposition in APPswe/PS1 E9 Mice With Hemizygous Deletions of TTR (Transthyretin)

Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area

Late-Onset Transthyretin (TTR)-familial Amyloid Polyneuropathy (FAP) With a Long Disease Duration From Non-Endemic Areas in Japan

The Prevalence and Distribution of the Amyloidogenic Transthyretin (TTR) V122I Allele in Africa

Autosomal-Dominant Transthyretin (TTR)-related Amyloidosis Is Not a Frequent CMT2 Neuropathy “In Disguise”

Extrapolation of Data From the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) Further Highlights the Survival Benefit of Tafamidis in Transthyretin Amyloid Cardiomyopathy

Refine Penetrance Estimates in the Main Pathogenic Variants of Transthyretin Hereditary (Familial) Amyloid Polyneuropathy (TTR-FAP) Using a New Non-Parametric Approach (NPSE)

A Case of Familial Amyloid Polyneuropathy Due to Phe33Val TTR With Vitreous Involvement as the Initial Manifestation